Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer To Purchase NextWave For ADHD Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer is exercising its option to buy privately held NextWave Pharmaceuticals. The acquisition, which is expected to close in the fourth quarter, will give Pfizer the recently approved ADHD drug Quillivant XR.


Related Content

Sale Of Pfizer’s Established Products Not Off The Table, Exec Says
Pfizer Moo’ved To Split Off Zoetis Business By July 2013
Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts